Bausch + Lomb (NYSE:BLCO) reported fourth-quarter revenue that surpassed Wall Street expectations, showcasing strong top-line momentum even as the global eye health company posted a net loss for the period.
The company announced a fourth-quarter net loss attributable to Bausch + Lomb of $58 million.
Despite the bottom-line deficit, core operational profitability remained solid.
The company reported fourth-quarter adjusted earnings before interest, taxes, depreciation, and amortization of $326 million.
Excluding acquired in-process research and development, that adjusted EBITDA figure stood at $330 million.
Top-line results comfortably beat market forecasts.
Bausch + Lomb posted revenue of $1.405 billion in the fourth quarter, representing a 10 percent increase on a reported basis and a 7 percent increase on a constant currency basis compared to the same period in 2024.
This performance outperformed the roughly $1.38 billion consensus estimate projected by Wall Street analysts.
For the full 2025 fiscal year, the eye care manufacturer reported a total GAAP net loss of $360 million.
Annual revenue reached $5.101 billion, climbing 6 percent as reported and 5 percent on a constant currency basis over the previous year.
Full-year adjusted EBITDA came in at $858 million, or $891 million when excluding acquired IPR&D, underscoring the company's steady execution across its product portfolios.